General Information of Drug (ID: DMVEYKS)

Drug Name
JSP191 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hematopoietic stem cell transplantation QB63 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMVEYKS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [3]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [4]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [5]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [6]
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [6]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [7]
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour 2F7B Approved [8]
Ripretinib DM958QB Gastrointestinal stromal tumour 2B5B Approved [9]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT05357482) Addition of JSP191 (C-kit Antibody) to Non-myeloablative Hematopoietic Cell Transplantation For Sickle Cell Disease and Beta-Thalassemia. U.S.National Institutes of Health.
2 Physiologically-based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency. CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1316-1327.
3 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
4 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
5 New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
10 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
11 National Cancer Institute Drug Dictionary (drug id 452042).